Although small molecules that activate the STING pathway could be a potentially promising strategy to improve immunotherapeutic efficiency in glioma, systemically administered STING agonists might induce undesired inflammation throughout the body due to the ubiquitous expression of STING in both tumor and normal tissues, which limits clinical administration to intratumoral routes only. Here, STING1 is linked to central nervous system cancer.